Literature DB >> 20478385

Phospholipase A2 activity is associated with structural brain changes in schizophrenia.

Stefan Smesny1, Berko Milleit, Igor Nenadic, Christoph Preul, Daniel Kinder, Jürgen Lasch, Ingo Willhardt, Heinrich Sauer, Christian Gaser.   

Abstract

Regional structural brain changes are among the most robust biological findings in schizophrenia, yet the underlying pathophysiological changes remain poorly understood. Recent evidence suggests that abnormal neuronal/dendritic plasticity is related to alterations in membrane lipids. We examined whether serum activity of membrane lipid remodelling/repairing cytosolic phospholipase A(2) (PLA(2)) were related to regional brain structure in magnetic resonance images (MRI). The study involved 24 schizophrenia patients, who were either drug-naïve or off antipsychotic medication, and 25 healthy controls. Using voxel-based morphometry (VBM) analysis of T1-high-resolution MRI-images, we correlated both gray matter and white matter changes with serum PLA(2)-activity. PLA(2) activity was increased in patients, consistent with previous findings. VBM group comparison of patients vs. controls showed abnormalities of frontal and medial temporal cortices/hippocampus, and left middle/superior temporal gyrus in first-episode patients. Group comparison of VBM/PLA(2)-correlations revealed a distinct pattern of disease-related interactions between gray/white matter changes in patients and PLA(2)-activity: in first-episode patients (n=13), PLA(2)-activity was associated with structural alterations in the left prefrontal cortex and the bilateral thalamus. Recurrent-episode patients (n=11) showed a wide-spread pattern of associations between PLA(2)-activity and structural changes in the left (less right) prefrontal and inferior parietal cortex, the left (less right) thalamus and caudate nucleus, the left medial temporal and orbitofrontal cortex and anterior cingulum, and the cerebellum. Our findings demonstrate a potential association between membrane lipid biochemistry and focal brain structural abnormalities in schizophrenia. Differential patterns in first-episode vs. chronic patients might be related to PLA(2)-increase at disease-onset reflecting localized regenerative activity, whereas correlations in recurrent-episode patients might point to less specific neurodegenerative aspects of disease progression. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20478385     DOI: 10.1016/j.neuroimage.2010.05.009

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  16 in total

Review 1.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

2.  Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?

Authors:  Maju Mathew Koola; Jeffrey K Raines; Robert G Hamilton; Robert P McMahon
Journal:  Curr Psychiatr       Date:  2016-04-25

3.  Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features.

Authors:  Marco Calabrò; Stefano Porcelli; Concetta Crisafulli; Sheng-Min Wang; Soo-Jung Lee; Changsu Han; Ashwin A Patkar; Prakash S Masand; Diego Albani; Ilaria Raimondi; Gianluigi Forloni; Sofia Bin; Carlotta Cristalli; Vilma Mantovani; Chi-Un Pae; Alessandro Serretti
Journal:  J Mol Neurosci       Date:  2017-11-21       Impact factor: 3.444

Review 4.  Lysophosphatidic Acid signaling in the nervous system.

Authors:  Yun C Yung; Nicole C Stoddard; Hope Mirendil; Jerold Chun
Journal:  Neuron       Date:  2015-02-18       Impact factor: 17.173

5.  Polyunsaturated fatty acid biostatus, phospholipase A2 activity and brain white matter microstructure across adolescence.

Authors:  Robert K McNamara; Philip R Szeszko; Stefan Smesny; Toshikazu Ikuta; Pamela DeRosse; Frédéric M Vaz; Berko Milleit; Uta-Christina Hipler; Cornelia Wiegand; Jana Hesse; G Paul Amminger; Anil K Malhotra; Bart D Peters
Journal:  Neuroscience       Date:  2016-12-18       Impact factor: 3.590

6.  Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

Authors:  S Smesny; B Milleit; U-C Hipler; C Milleit; M R Schäfer; C M Klier; M Holub; I Holzer; G E Berger; M Otto; I Nenadic; M Berk; P D McGorry; H Sauer; G P Amminger
Journal:  Mol Psychiatry       Date:  2013-03-12       Impact factor: 15.992

7.  Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism.

Authors:  Stefan Smesny; Christian E H Schmelzer; Anke Hinder; Alexandra Köhler; Christiane Schneider; Maria Rudzok; Ulrike Schmidt; Berko Milleit; Christine Milleit; Igor Nenadic; Heinrich Sauer; Reinhard H H Neubert; Joachim W Fluhr
Journal:  Schizophr Bull       Date:  2012-05-15       Impact factor: 9.306

8.  Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia.

Authors:  Matej Orešič; Tuulikki Seppänen-Laakso; Daqiang Sun; Jing Tang; Sebastian Therman; Rachael Viehman; Ulla Mustonen; Theo G van Erp; Tuulia Hyötyläinen; Paul Thompson; Arthur W Toga; Matti O Huttunen; Jaana Suvisaari; Jaakko Kaprio; Jouko Lönnqvist; Tyrone D Cannon
Journal:  Genome Med       Date:  2012-01-18       Impact factor: 11.117

9.  Increased PLA2 activity in individuals at ultra-high risk for psychosis.

Authors:  Leda L Talib; Alana C Costa; Helena P G Joaquim; Cícero A C Pereira; Martinus T Van de Bilt; Alexandre A Loch; Wagner F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-03-06       Impact factor: 5.270

Review 10.  Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?

Authors:  Ariel Frajerman; Linda Scoriels; Oussama Kebir; Boris Chaumette
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.